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Abstract
Aim: To examine the metabolic, gluco-regulatory-hormonal and inflammatory cytokine responses to large reductions in
rapid-acting insulin dose administered prandially before and after intensive running exercise in male type 1 diabetes
patients.
Methods: This was a single centre, randomised, controlled open label study. Following preliminary testing, 8 male patients
(2462 years, HbA1c 7.760.4%/6164 mmol.l21) treated with insulin’s glargine and aspart, or lispro attended the laboratory
on two mornings at ,08:00 h and consumed a standardised breakfast carbohydrate bolus (1 g carbohydrate.kg21BM;
380610 kcal) and self-administered a 75% reduced rapid-acting insulin dose 60 minutes before 45 minutes of intensive
treadmill running at 73.160.9% VO2peak. At 60 minutes post-exercise, patients ingested a meal (1 g carbohydrate.kg
21BM;
660621 kcal) and administered either a Full or 50% reduced rapid-acting insulin dose. Blood glucose and lactate, serum
insulin, cortisol, non-esterified-fatty-acids, b-Hydroxybutyrate, and plasma glucagon, adrenaline, noradrenaline, IL-6, and
TNF-a concentrations were measured for 180 minutes post-meal.
Results: All participants were analysed. All glycaemic, metabolic, hormonal, and cytokine responses were similar between
conditions up to 60 minutes following exercise. Following the post-exercise meal, serum insulin concentrations were lower
under 50% (p,0.05) resulting in 75% of patients experiencing hyperglycaemia (blood glucose $8.0 mmol.l21; 50% n= 6,
Full n= 3). b-Hydroxybutyrate concentrations decreased similarly, such that at 180 minutes post-meal concentrations were
lower than rest under Full and 50%. IL-6 and TNF-a concentrations remained similar to fasting levels under 50% but
declined under Full. Under 50% IL-6 concentrations were inversely related with serum insulin concentrations (r=20.484,
p= 0.017).
Conclusions: Heavily reducing rapid-acting insulin dose with a carbohydrate bolus before, and a meal after intensive
running exercise may cause hyperglycaemia, but does not augment ketonaemia, raise inflammatory cytokines TNF-a and IL-
6 above fasting levels, or cause other adverse metabolic or hormonal disturbances.
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Introduction
Cardiorespiratory or endurance-based exercise is promoted as
playing an integral role in maintaining a healthy lifestyle for
patients with type 1 diabetes because of its utility to enhance
cardiovascular fitness, improve anthropometrics and reduce total
daily insulin requirements (see Chu et al [1]). Although this form of
exercise carries blood glucose lowering effects which may initially
offer some therapeutic benefit, reductions in blood glucose
following exercise are often excessive, exposing patients to
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hypoglycaemia [2]. To reduce the incidence of hypoglycaemia
during and immediately after exercise, patients are recommended
to reduce their pre-exercise rapid-acting insulin dose [2,3].
However, recent evidence also suggests that it is important for
patients to reduce the dose of rapid-acting insulin administered
with the meal after exercise as well, so that the risk of post-exercise
hypoglycaemia is abated [4].
In combining pre and post-exercise rapid-acting insulin dose
reductions some patients may be exposed to periods of hypergly-
caemia [4]. With this is mind, it is reasonable to speculate that low
levels of circulating insulin combined with elevated concentrations
of post-exercise counter-regulatory hormones may in fact precip-
itate a metabolic milieu promoting increased lipolysis [5] and
ketogenesis [6]. In addition, inflammatory cytokine responses are
related to hyperglycaemia [7–10], lipid oxidation [11], and/or
hyperketonaemia [12–14]. Although regular exercise has been
demonstrated to reduce systemic inflammation, thus strengthening
its therapeutic utility for patients with type 1 diabetes [15],
somewhat paradoxically, these long-term adaptations occur
despite opposing acute effects in which there is a pronounced
increase in inflammatory markers early after exercise [16–21].
Potentially, performing exercise under conditions of concurrent
or prior hyperglycaemia and/or hypoinsulinaemia might result in
an inappropriately elevated level of inflammation after exercise.
Additionally, metabolic disturbances could negate the over-all
health benefits of exercise and promote the onset and progression
of diabetic complications. Indeed, this may offer some explanation
towards conflicting opinion regarding the efficacy of aerobic or
endurance-based exercise for improvements in glycaemic control,
with some literature demonstrating no improvement or even
worsening HbA1c (for review see Tonoli et al [22]).
It is a well-established recommendation that patients reduce
their pre-exercise rapid-acting insulin dose to prevent exercise-
induced hypoglycaemia, and the metabolic implications of this are
well known [23]. However, the deeper metabolic consequences of
employing the recently advocated strategy of heavily reducing
both pre and post-exercise rapid-acting insulin dose [4] are
unknown. Therefore, the aim of this study was to determine
whether reducing pre- and also post-exercise rapid-acting insulin
dose, as a strategy for preventing post-exercise hypoglycaemia,
causes metabolic or hormonal disturbances, influences ketonae-
mia, or alters inflammatory cytokine concentrations in type 1
diabetes patients, following intensive running exercise.
Methods
Ethics statement
This study was approved by local National Health Service
Research Ethics Committee (13/NE/0016); registry details
(NCT01531855, ClinicalTrials.gov). All patients who participated
provided full written informed consent. All clinical investigations
were conducted according to the principles expressed in the
Declaration of Helsinki. The study was conducted between 1st
March 2013 and 1st September 2013.
Protocol
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Checklist S1 and
Protocol S1. Eight male type 1 diabetes patients (mean 6 SEM;
age 2462 years, BMI 22.960.7, duration of diabetes 1362 years,
HbA1c 7.760.4%/6164 mmol.l
21, _VO2peak 5461 ml.kg.min
21)
volunteered to participate. Female participants were not included
due to the potential influence of the menstrual cycle on blood
glucose homeostasis [24]. Interested patients who met the
eligibility criteria for involvement in the study (aged between
18–35 years with a duration of diabetes greater than 2 years on
enrolment, treated with a stable basal-bolus insulin regimen
composed of insulin glargine and fast-acting insulin aspart or lispro
for a minimum of 6 months, free of diabetes related complications,
and receiving no additional medication other than insulin) were
screened in-line with the procedures of American College of
Sports Medicine’s (ACSM) Guidelines for Exercise Testing and
Prescription [25]. Screening measures included a comprehensive
medical questionnaire and the completion of a cardiopulmonary
exercise stress test to assess cardiac function in response to
exercise. All patients were regularly and consistently active (self-
reporting to participate in aerobic based exercise for at least 30
minutes at a time, 3 times per week), and displayed normal cardio-
pulmonary responses to exercise. All patients were familiar with
carbohydrate counting. Patients underwent randomisation using a
computer programme to determine the sequence of two open label
crossover arms.
Upon completion of the screening procedures, patients com-
pleted a preliminary incremental treadmill test to quantify peak
cardio-respiratory parameters as described previously by our
group [2,4]. Following this, patients attended the Newcastle NIHR
Clinical Research Facility exercise laboratory on two occasions,
once per week at ,08:00 h. Patients replicated their diet (assessed
using weighed dietary recording sheets) and maintained a similar
insulin regimen (with basal insulin dose standardised i.e. dose,
injection site, time of injection) during the 24 hours preceding
each trial. Additionally, patients were required to avoid exercise
for 24 hours prior to each visit; activity patterns were measured
using a pedometer (Omron Healthcare Europe B.V., Nether-
lands). Patients maintained their usual basal regimen (dose,
injection site, time of injection) between trials.
Patients arrived at the laboratory after an overnight fast; if
patients experienced a hypoglycaemic episode on the preceding
night their trial was rescheduled. Following their arrival, patients
assumed a resting position while a 20 gauge cannula (Vasofix,
B.Braun Melsungen AG, Germany) was inserted into the
antecubital vein of their non-dominant arm. An 11 ml resting
venous blood sample was taken, of which 20 ml was analysed
immediately for glucose (BG) and lactate (Biosen C-Line, EKF
Diagnostic GmbH, Germany), and 10 ml analysed for haemoglo-
bin and haematocrit (Hemo Control, EKF-diagnostic GmbH,
Germany) which was used to correct for changes in plasma volume
[26]. The remaining sample was dispensed evenly into Lithium-
heparin tubes (Vacuette, Greiner Bio-One GmBH, Austria) and
serum separation tubes (Vacuette, Greiner Bio-One GmBH,
Austria) which were centrifuged for 15 minutes at 3000 rev.min21,
and stored at 280uC for later analysis of rapid-acting insulin
(Invitron insulin assay, Invitron, UK), glucagon (Glucagon EIA,
Sigma-Aldrich, USA), adrenaline and noradrenaline (BI-CAT
adrenaline and noradrenaline ELISA, Eagle Biosciences, UK),
cortisol (Parameter cortisol ELISA, R & D Systems, Roche
Diagnostics, UK), non-esterified-fatty-acids (NEFA; Non-esterified
fatty acids colorimetric assay, Randox Laboratories, UK), b-
Hydroxybutyrate (D-3-Hydroxybutyrate kinetic enzymatic assay,
Randox Laboratories, UK), interleukin-6 (IL-6; Human IL-6
Quantikine ELISA, R & D Systems, Roche Diagnostics, UK) and
tumour necrosis factor alpha (TNF-a; Human TNF-alpha
Quantikine ELISA, R & D Systems, Roche Diagnostics, UK).
The coefficient of variation was ,10% for all assays.
Following the resting sample, patients were provided with a
standardised cereal-based breakfast-carbohydrate bolus (frosted
flakes, semi-skimmed milk, peaches) equating to 1 g carbohydra-
te.kg21BM (380610 kcal; 1.5960.04 MJ). Immediately before
Pre- and Post-Exercise Rapid-Acting Insulin Reductions
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consumption, patients administered a 25% (1.860.1 IU) dose (i.e.
a 75% reduction) of rapid-acting insulin into the abdomen, as per
current recommendations [2,3]. This pre-exercise carbohydrate
and insulin strategy was based on previously published method-
ologies [3,27]. All patients were administering 1.060.1 IU of
rapid-acting insulin per 10 g of carbohydrate. The injection site
was standardised across trials through administration at half the
distance between the anterior-superior iliac crest and the naval.
Insulin aspart and lispro were administered using Novopen3
(NovoNordisk, UK) and Humapen luxura (Eli Lilly, UK),
respectively.
A further blood sample was collected at 60 minutes following
the ingestion of the breakfast meal. At 60 minutes, patients
performed a 45 minute bout of treadmill running (Woodway,
Germany) at a velocity calculated to elicit 70%VO2peak. During
exercise, breath-by-breath respiratory parameters (MetaLyzer 3B;
Cortex, Germany) and heart rate (S810; Polar, Finland) were
continuously recorded. Immediately upon cessation of exercise, a
blood sample was obtained with further blood samples collected at
15, 30, and 60 minutes post-exercise. At 60 minutes post-exercise,
patients were provided with a pasta-based lunch (pasta, tomato
based sauce, cheddar cheese) equating to 1 g carbohydra-
te.kg21BM (660621 kcal; 2.7660.09 MJ) to which they admin-
istered either a Full (7.560.3 IU) or 50% (3.760.1 IU) rapid-
acting insulin dose immediately before consumption, into the
contralateral abdominal site to that which received the pre-
exercise rapid-acting insulin dose. Having consumed the meal,
patients remained rested for 180 minutes with periodic blood
samples every 30 minutes. Hypoglycaemia was defined as a blood
glucose concentration of #3.9 mmol.121 and hyperglycaemia as
$8.0 mmol.121. If patients experienced hypoglycaemia during
the laboratory period a 20 g carbohydrate bolus was administered
(Lucozade, GlaxoSmithKline, UK). Hyperketonaemia was defined
as a b-hydroxybutyrate concentration .1.0 mmol.l21 [6].
Data analysis
Sample size was calculated using data from Campbell et al [4]
and the methods of Hopkins [28] whereby the number of
participants required is based around the precision defined by
95% confidence limits (deriving a power 0.8). The sample size is
calculated as n =8s2/d2 where n is the samples size, s is the typical
error, and d is the smallest worthwhile effect. A sample size of 8
participants was required to achieve 80% power. Statistical
analysis was performed using PASW Statistics software (IBM
PASW version 18; IBM., NY, USA) with significance set at p#
0.05. Interactions of time and condition were examined using
repeated measures ANOVA. Where significant p-values were
identified for interaction effects (time*condition), insulin dose was
deemed to have influenced the response, and simple main effects
analyses were performed. Significant main effects of time were
further investigated using BONFERRONI adjusted pairwise
comparisons. One-way repeated ANOVA were performed where
relevant and relationships were explored using Pearson’s product
moment correlation coefficient. Data are presented as mean 6
SEM.
Results
All patients were analysed for this study. A significant
interaction of condition and time were evident when examining
serum insulin (p,0.001) and blood glucose (condition*time,
p=0.014). Serum insulin (Figure 1A) and blood glucose
(Figure 1B) concentrations were similar between conditions at
baseline and immediately before exercise. The performance of
exercise was intensive, with patients exercising at a similar % of
_VO2peak (Full 74.560.01; 50% 71.660.02% _VO2peak, p=0.329),
and HRpeak (Full 8062; 50% 7961%HRpeak, p=0.785). The
average respiratory exchange ratio during exercise was similar
between conditions (Full 0.9860.01; 50% 0.9660.02, p=0.256),
resulting in similar reductions in blood glucose (Full 27.860.8;
50% 27.561.11 mmol.l21, p=0.453, Figure 1B) and similar
peaks in blood lactate. Serum insulin (Figure 1A) and blood
glucose (Figure 1B) concentrations up to 60 minutes post-exercise
were similar between conditions, such that blood glucose was
comparable immediately prior to the administration of the post-
exercise meal (Figure 1B).
Following the post-exercise meal, serum insulin peaked at 60
minutes under both conditions, with mean peak concentrations
greater under Full (199647; 50% 109628 pmol.l21, p=0.021;
Figure 1A). From 60 minutes post-meal, serum insulin under Full
remained elevated from pre-meal measures, and significantly
higher than 50% (p,0.05; Figure 1A). Blood glucose declined
under Full (Figure 1B), but was preserved under 50% with
concentrations greater than those at pre-meal throughout the
three hour observation period (Figure 1B). During this time, 63%
of patients (n = 5) experienced hypoglycaemia (BG#3.9 mmol.l21)
under Full, whereas all patients under 50% were protected.
Inversely, fewer patients under Full experienced hyperglycaemia
(BG$8 mmol.l21; Full n= 3; 50% n= 6).
There were no conditional differences in counter-regulatory
hormones (Table 1) or metabolites (Table 2) up to 60 minutes post-
exercise (p.0.05). A significant interaction of condition and time
(p=0.006) were found when examining plasma glucagon concen-
trations during the trials (Table 2). Plasma glucagon concentra-
tions following the post-exercise meal were significantly elevated
from pre-meal values under both conditions, but were highest
under Full (Table 1). There were no differences in b-Hydroxy-
butyrate, adrenaline, noradrenaline, cortisol, blood lactate, or
NEFA concentrations between conditions following the post-
exercise meal (Table 1 and 2). During this time, there was a
transient decline in b-Hydroxybutyrate with concentrations similar
to rest under 50% and lower than rest under Full (Table 2).
The IL-6 and TNF-a responses are presented in Figure 2 A–B.
Plasma TNF-a concentrations were significantly raised at 15
minutes post-exercise. Following the post-exercise meal, IL-6
concentrations were significantly greater under 50%. However,
TNF-a was similar between conditions. Despite this, both
cytokines under 50% remained similar to pre-meal and resting
measures (p.0.05; Figure 2A–B). Under 50% mean IL-6
concentrations over the post-exercise period were positively
related to mean TNF-a concentrations (r=0.676, p,0.001) and
serum insulin concentrations were inversely related to IL-6 (r=2
0.484, p=0.017), but not TNF-a (r=20.169, p=0.430). No
significant relationships existed between mean blood glucose and
IL-6 (r=0.299, p=0.155) or TNF-a (r=0.005, p=0.980) over the
post-meal period under 50%. No relationships were found
between any measures under Full.
Discussion
To our knowledge we are the first to demonstrate, that
manipulating pre- and also post-exercise rapid-acting insulin dose,
as a strategy for preventing post-exercise hypoglycaemia does not
cause adverse metabolic or counter-regulatory-hormonal distur-
bances yet patients remain protected from hypoglycaemia.
Specifically, our data indicate that large reductions in rapid-acting
insulin dose administered before and also after intensive running
exercise may cause post-exercise hyperglycaemia, but this strategy
Pre- and Post-Exercise Rapid-Acting Insulin Reductions
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does not augment ketonaemia in patients with type 1 diabetes. In
addition, we demonstrate that inflammatory cytokines may
increase with this strategy, but not above fasting concentrations,
and by 180 minutes post-meal the pro-inflammatory cytokine
TNF-a is lower than rest.
Patients completed an intensive bout of prolonged running
exercise, running at an average speed of 9.360.3 km.hr21 and
covering a distance of 7.060.2 km. The respiratory exchange ratio
(,0.96) exhibited by patients is typical of exercise of an intense
nature [29], and reflects the predominant use of carbohydrate
during exercise. Indeed, completing the exercise protocol caused a
significant metabolic stress to patients, inducing large increases in
blood lactate (,392%) and catecholamines (adrenaline ,287%,
noradrenaline ,591%), and large decreases in blood glucose
(D,7.6 mmol.l21). Despite subsequent reductions in glycaemia,
and the administration of a second dose of rapid-acting insulin 60
minutes post-exercise, all patients under 50% were protected from
hypoglycaemia throughout their laboratory stay. As such, we
demonstrate that administering a small dose of rapid-acting insulin
with a carbohydrate bolus before exercise is effective in limiting
pre-exercise hyperglycaemia and preventing hypoglycaemia dur-
ing and immediately after exercise. Importantly, circulating insulin
concentrations following exercise returned to baseline, meaning
the effects of administering a pre-exercise rapid-acting insulin dose
Figure 1. A–B. Time-course changes in serum insulin (A) and blood glucose (B) from rest. Full = black squares, 50% = black diamond.*
indicates significantly different from Full (p,0.05). Transparent sample point within a condition indicates a significant difference from pre-exercise
meal concentrations (p,0.05). Vertical dashed line break indicates post-exercise intervention. NOTE: test meal and insulin were administered
immediately following rest and meal sample points.
doi:10.1371/journal.pone.0097143.g001
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Table 1. Counter-regulatory responses to reductions in pre- and post-exercise rapid-acting insulin dose during the experimental trials.
ANOVA p
Rest 60 Exercise 0 15 30 Pre-Meal 30 60 90 120 150 180 Time Time*Condition
Plasma
Glucagon
(pg.ml21)
Full 760670 697681 - 1152699{ 832683{ 698661 710669 1015679{` 15976116{` 15906102{` 1402694{` 13326137{` 10996124{` ,0.001 = 0.006
50% 789685 628685{* - 10676128{ 8546127 815689 609698{ 975682{` 1350696{*` 1251697{*` 1177690{*` 1085686{*` 889682*`
Plasma
Adrenaline
(nmol.l21)
Full 0.3060.05 0.1460.04{ - 0.6360.11{ 0.4960.12 0.3760.08 0.2660.06 0.2460.06 0.2360.10 0.1460.05{ 0.1960.06 0.2160.07 0.1660.05{` ,0.001 = 0.808
50% 0.3060.07 0.2160.05 - 0.6860.08{ 0.3460.05 0.2360.05 0.1660.04 0.1660.05 0.1760.04 0.1660.05 0.1760.06 0.1660.04 0.1560.04
Plasma
Noradrenaline
(nmol.l21)
Full 2.1160.33 1.7260.27 - 12.9861.56{ 4.7660.69{ 3.1560.36{ 2.5960.36 2.6560.33 2.7260.46 2.3660.37 2.3960.48 2.3060.42 2.2160.43 ,0.001 = 0.407
50% 2.2560.34 2.1760.32 - 13.6361.84{ 4.1660.35{ 3.3460.25{ 2.7160.34 2.6760.52 2.8760.61 2.6260.47 2.9060.73 2.9260.68 2.7760.61
Serum Cortisol
(nmol.l21)
Full 0.2360.04 0.2260.03{ - 0.2160.03{ 0.2560.03 0.2260.03 0.1860.02{ 0.1860.03{ 0.1660.03{` 0.1260.02{` 0.1260.03{ 0.1060.01{ 0.1060.01{ = 0.019 = 0.394
50% 0.2260.04 0.1860.05{ - 0.2060.03 0.24 60.04 0.2260.03 0.1860.02 0.1560.02 0.1260.02{ 0.1360.03{ 0.1160.02 0.0960.01 0.0760.01
NOTE: Data presented as mean 6 SEM. Test meal and insulin were administered immediately following rest and pre-meal sample points.
* indicates significantly different from Full (p#0.05).
{indicates significantly different from rest.
`indicates significantly different from pre-meal.
NOTE: Exercise commenced 60 minutes after rest.
doi:10.1371/journal.pone.0097143.t001
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of this size is unlikely to carry additive effects for subsequent post-
exercise rapid-acting insulin administration. Therefore, reducing
pre- and also post-exercise rapid-acting insulin dose is an effective
strategy for preventing exercise-induced hypoglycaemia. However,
preserving glycaemia consequently exposed patients under 50% to
periods of hyperglycaemia following the post-exercise meal. This
finding emphasises that patients differ in their sensitivity to insulin
following exercise, and as such, we advise that patients may
require a smaller reduction in post-exercise rapid-acting insulin
dose.
Although the majority of patients under 50% were exposed to
hyperglycaemia, b-Hydroxybutyrate concentrations following the
post-exercise meal remained similar between both conditions, with
values remaining less than those considered hyperketonaemic (,
1.0 mmol.l21) [6] and similar to rest. Although we applied a large
reduction in rapid-acting insulin dose, serum insulin concentra-
tions were elevated above resting and pre-meal measures under
50% (Table 1). Despite unexplained differences in glucagon
concentrations, the administration of even small amounts of rapid-
acting insulin, under conditions of unchanged basal insulin dose, is
likely to have raised circulating insulin concentrations to a level
where b-Hydroxybutyrate production was suppressed [30], and
potentially augment peripheral ketone body disposal [31].
Additionally, NEFA concentrations did not increase, likely
attributable to unchanged concentrations of catecholamines, the
main lipolytic stimulus [32], and cortisol [33]. Furthermore, the
consumption of a large carbohydrate based meal would have
helped supplement muscle and liver glycogen, reducing the energy
deficit created by exercise, and limiting the appearance of
catecholamines and cortisol.
We questioned whether post-exercise hyperglycaemia would
exacerbate the appearance of inflammatory cytokines in our
patients, indeed this may be further exacerbated if patients
experienced hyperketonaemia. Hyperglycaemia associated inflam-
mation is a major contributor to the pathogenesis of diabetes
related complications [9,33], which are primarily avoided through
the normalisation of glycaemic profiles [34]. Patients with type 1
diabetes exhibit chronically elevated levels of inflammatory
markers at baseline [7–10,35]. Baseline measures were elevated
above some of those previously reported [7,35–38], which may
have resulted from patients arriving in a fasted state and with low
circulating concentrations of insulin. However, comparison
between studies is hampered by mixed methodologies and
differing patient characteristics, indeed most studies implement
glucose and/or insulin clamp procedures, and recruit children or
adolescents who are usually recently diagnosed [7,35–38]. Our
study population consisted of a relatively young (,24 years) group
of individuals all in good glycaemic control (,7.7%/
61 mmol.l21), exposure to inflammatory stimuli is likely to be
much greater in the general diabetes population who are older,
have a longer duration of diabetes, and in those with excess
adiposity [10].
We witnessed only modest increases in IL-6 (,22%) and TNF-a
(,45%) following exercise, which is likely due to the administra-
tion of the pre-exercise meal and concomitant insulin in our
patients. The large carbohydrate bolus (1.0 g carbohydrate.kg21
BM) would have helped supplement glycogen reserves [39], which
may have attenuated the exercise-induced increases in IL-6
[12,40] and even completely inhibited IL-6 release from contract-
ing skeletal muscle [40]. In addition, insulin carries anti-
inflammatory properties [41], of which its administration, even
in small doses, may have partially combatted the pro-inflamma-
tory effects of TNF-a. Indeed, IL-6 concentrations were inversely
related to circulation insulin concentrations. IL-6 has anti- as well
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as pro-inflammatory properties, with some studies demonstrating
IL-6 to exert inhibitory effects on TNF-a. We found there to be a
positive correlation between IL-6 and TNF-a. Although a
relationship does not necessarily indicate cause-effect, speculative-
ly, increases in IL-6 may indeed have been in direct response to
reducing TNF-a. Irrelevant of the mechanisms at play, our data
indicate that TNF-a or IL-6 are not significantly elevated above
fasting concentrations, and that by 180 minutes post-meal,
concentrations are lower than those following an overnight fast.
We chose IL-6 and TNF-a as our main inflammatory markers,
in part, because both display the greatest quantitative change [40]
and therefore have a high likelihood to yield distinct differences
between our study conditions [16,20,35,37]. There is however, a
known and marked inherent variability of many inflammatory
markers [7,37], which reflects the remarkable metabolic complex-
ity of that patient with type 1 diabetes in which permutations in
inflammation status are variable across patients and within the
same individuals overtime [7]. Indeed, some of this variability is
attributed to antecedent hyperglycaemia [7,16–21,36,38], howev-
er patients in this study were kept under free-living conditions
before experimentation and without correction using euglycaemic
clamp procedures, and therefore likely to closely replicate the
responses in patients in day-to-day life. It would be inappropriate
to conclude that inflammation per se was unchanged in our
patients, as we were only able to analyse two inflammatory
cytokines within our dataset. Although TNF-a and IL-6 are
Figure 2. A–B. Time-course changes in IL-6 (A) and TNF-a (B) from rest. Full = black squares, 50% = black diamond.* indicates significantly
different from Full (p,0.05). Transparent sample point within a condition indicates a significant difference from pre-exercise meal concentrations (p,
0.05). Vertical dashed line break indicates post-exercise intervention. NOTE: test meal and insulin were administered immediately following rest and
meal sample points.
doi:10.1371/journal.pone.0097143.g002
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readily accepted as primary markers of inflammation, future
research investigating more detailed post-prandial inflammatory
responses in this population is warranted.
An interesting finding was that plasma glucagon concentrations
following the post-exercise meal were elevated under both
conditions, and significantly greater under Full. Although the
majority of patients under this condition experienced hypoglycae-
mia (BG#3.9 mmol.l21; 50% n= 0, Full n=5), patients were
treated with a corrective bolus of carbohydrate, such that blood
glucose levels (group mean BG,6.6 mmol.l21) remained above
the glycaemic threshold for plasma glucagon release (BG,
3.0 mmol.l21; [42]; even if an appropriate glycaemic threshold
was achieved to stimulate glucagon release, it would remain a
surprise to find any increase in glucagon concentrations in our
patients, as its secretion under exercising and hypoglycaemic
conditions is blunted in type 1 diabetes [42]. In addition, increased
glucagon response to a mixed-meal stimulus has been noted
previously in type 1 diabetes [43], suggestive that the a-cell
secretory reserve may be unaffected by the progression of the
autoimmune process [43]. Of note, the meal administered in the
study by Brown et al [43], was similar in nutritional content to the
post-exercise meal given to patients in our study (Carbohydrate 56
vs. 53%; Protein 21 vs. 25%, Fat 21 vs. 22%), although our meal
was larger (400 kcal vs.,660 kcal). Considering all of our patients
had longstanding diabetes (length of disease ,13 years), were
intensively controlled (,7.7%/61 mmol.l21), and therefore likely
to have been frequently exposed to hypoglycaemia, investigation
of differing types of post-exercise meal may be an important
avenue to investigate as altering the composition or glycaemic
index of the post-exercise meal may indeed offer more favourable
glycaemic profiles by reducing the incidence of hyperglycaemia.
To conclude, heavily reducing pre- and post-exercise rapid-
acting insulin dose does not induce hyperketonaemia, excessively
raise inflammatory cytokines TNF-a or IL-6, or cause other
metabolic or hormonal disturbances in type 1 diabetes patients
treated with insulin glargine and fast-acting insulin aspart or lispro.
In addition, we further highlight the importance of this strategy in
preventing early-onset post-exercise hypoglycaemia. However,
patients may be exposed to hyperglycaemia and are therefore
encouraged to regularly monitor blood glucose concentrations
after exercise, and refine these strategies such that euglycaemia
can be achieved following individual exercise routines. We advise
that future research investigates in more detail post-prandial
inflammatory responses in this population.
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